JOSLIN DIABETES CENTER

Novo Nordisk and Evotec select three projects for LAB eN², focusing on cardiometabolic diseases. LAB eN² expands to include Boston Children's Hospital, Johns Hopkins University, and others. The initiative leverages Evotec's R&D platform and Novo Nordisk's disease expertise for drug discovery.

Evotec SE and Novo Nordisk select first three projects for LAB eN² drug discovery accelerator, focusing on cardiometabolic diseases from Boston University, Harvard University, and Joslin Diabetes Center. The program expands to include five new academic institutions, offering initial Discovery Award funding and potential additional funding up to IND application stage, with Novo Nordisk maintaining the option to further develop and license specific programs.

USC's Keck School of Medicine launches a $2.7 million NIH-funded, multi-site study to understand how type 1 diabetes affects brain development in children, aiming to refine clinical guidelines and therapeutic approaches.